Exaggerated Cardiotoxicity of Sunitinib in Stressed 3-Dimensional Heart Muscles

Eschenhagen, Thomas

doi:10.1016/j.jacbts.2018.01.011

Cited by 4 publications

(1 citation statement)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Engineered 3D microtissues from hiPSC‐CMs have been used to explore the mechanisms underlying sunitinib‐induced cardiotoxicity . Correlating with previous findings, Truitt et al described a preclinical model that recapitulates cell death and increased caspase 3/7 activation following sunitinib exposure .…”

Section: Tissue Engineeringmentioning

confidence: 91%

Concise Review: Precision Matchmaking: Induced Pluripotent Stem Cells Meet Cardio-Oncology

Nair

Prado

Perea‐Gil

et al. 2019

Stem Cells Translational Medicine

View full text Add to dashboard Cite

As common chemotherapeutic agents are associated with an increased risk of acute and chronic cardiovascular complications, a new clinical discipline, cardio‐oncology, has recently emerged. At the same time, the development of preclinical human stem cell‐derived cardiovascular models holds promise as a more faithful platform to predict the cardiovascular toxicity of common cancer therapies and advance our understanding of the underlying mechanisms contributing to the cardiotoxicity. In this article, we review the recent advances in preclinical cancer‐related cardiotoxicity testing, focusing on new technologies, such as human induced pluripotent stem cell‐derived cardiomyocytes and tissue engineering. We further discuss some of the limitations of these technologies and present future directions. Stem Cells Translational Medicine 2019;8:758&767

show abstract

Section: Tissue Engineeringmentioning

confidence: 91%

Concise Review: Precision Matchmaking: Induced Pluripotent Stem Cells Meet Cardio-Oncology

Nair

Prado

Perea‐Gil

et al. 2019

Stem Cells Translational Medicine

View full text Add to dashboard Cite

show abstract

Upregulation of phosphoinositide 3-kinase prevents sunitinib-induced cardiotoxicity in vitro and in vivo

Zou

Zhang

et al. 2019

Arch Toxicol

View full text Add to dashboard Cite

Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management

Sunder

Sharma

Pokharel

2023

Sig Transduct Target Ther

112

View full text Add to dashboard Cite

Since their invention in the early 2000s, tyrosine kinase inhibitors (TKIs) have gained prominence as the most effective pathway-directed anti-cancer agents. TKIs have shown significant utility in the treatment of multiple hematological malignancies and solid tumors, including chronic myelogenous leukemia, non-small cell lung cancers, gastrointestinal stromal tumors, and HER2-positive breast cancers. Given their widespread applications, an increasing frequency of TKI-induced adverse effects has been reported. Although TKIs are known to affect multiple organs in the body including the lungs, liver, gastrointestinal tract, kidneys, thyroid, blood, and skin, cardiac involvement accounts for some of the most serious complications. The most frequently reported cardiovascular side effects range from hypertension, atrial fibrillation, reduced cardiac function, and heart failure to sudden death. The potential mechanisms of these side effects are unclear, leading to critical knowledge gaps in the development of effective therapy and treatment guidelines. There are limited data to infer the best clinical approaches for the early detection and therapeutic modulation of TKI-induced side effects, and universal consensus regarding various management guidelines is yet to be reached. In this state-of-the-art review, we examine multiple pre-clinical and clinical studies and curate evidence on the pathophysiology, mechanisms, and clinical management of these adverse reactions. We expect that this review will provide researchers and allied healthcare providers with the most up-to-date information on the pathophysiology, natural history, risk stratification, and management of emerging TKI-induced side effects in cancer patients.

show abstract

Exaggerated Cardiotoxicity of Sunitinib in Stressed 3-Dimensional Heart Muscles

Abstract: Corresponding Author

Cited by 4 publications

References 25 publications

Concise Review: Precision Matchmaking: Induced Pluripotent Stem Cells Meet Cardio-Oncology

Concise Review: Precision Matchmaking: Induced Pluripotent Stem Cells Meet Cardio-Oncology

Upregulation of phosphoinositide 3-kinase prevents sunitinib-induced cardiotoxicity in vitro and in vivo

Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management

Contact Info

Product

Resources

About